Literature DB >> 18201945

Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.

Sarah Zohar1, Satoshi Teramukai, Yinghui Zhou.   

Abstract

The aim of phase II single-arm clinical trials of a new drug is to determine whether it has sufficient promising activity to warrant its further development. For the last several years Bayesian statistical methods have been proposed and used. Bayesian approaches are ideal for earlier phase trials as they take into account information that accrues during a trial. Predictive probabilities are then updated and so become more accurate as the trial progresses. Suitable priors can act as pseudo samples, which make small sample clinical trials more informative. Thus patients have better chances to receive better treatments. The goal of this paper is to provide a tutorial for statisticians who use Bayesian methods for the first time or investigators who have some statistical background. In addition, real data from three clinical trials are presented as examples to illustrate how to conduct a Bayesian approach for phase II single-arm clinical trials with binary outcomes.

Entities:  

Mesh:

Year:  2007        PMID: 18201945     DOI: 10.1016/j.cct.2007.11.005

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  10 in total

1.  Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.

Authors:  Véronique Baudouin; Corinne Alberti; Anne-Laure Lapeyraque; Albert Bensman; Jean-Luc André; Françoise Broux; Mathilde Cailliez; Stéphane Decramer; Patrick Niaudet; Georges Deschênes; Evelyne Jacqz-Aigrain; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2011-09-28       Impact factor: 3.714

Review 2.  Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies.

Authors:  Rick L M Haas; Aisha B Miah; Cécile LePechoux; Thomas F DeLaney; Elizabeth H Baldini; Kaled Alektiar; Brian O'Sullivan
Journal:  Radiother Oncol       Date:  2015-12-21       Impact factor: 6.280

3.  A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.

Authors:  Chunyan Cai; Suyu Liu; Ying Yuan
Journal:  Stat Med       Date:  2014-05-12       Impact factor: 2.373

Review 4.  Equal access to innovative therapies and precision cancer care.

Authors:  Agnès Buzyn; Jean-Yves Blay; Natalie Hoog-Labouret; Marta Jimenez; Frédérique Nowak; Marie-Cécile Le Deley; David Pérol; Christian Cailliot; Jacques Raynaud; Gilles Vassal
Journal:  Nat Rev Clin Oncol       Date:  2016-03-22       Impact factor: 66.675

5.  Comparing Bayesian early stopping boundaries for phase II clinical trials.

Authors:  Liyun Jiang; Fangrong Yan; Peter F Thall; Xuelin Huang
Journal:  Pharm Stat       Date:  2020-07-27       Impact factor: 1.234

6.  Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach.

Authors:  Florentia Kaguelidou; Corinne Alberti; Valerie Biran; Olivier Bourdon; Caroline Farnoux; Sarah Zohar; Evelyne Jacqz-Aigrain
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

7.  The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.

Authors:  Leanne McCabe; Ian R White; Nguyen Van Vinh Chau; Eleanor Barnes; Sarah L Pett; Graham S Cooke; A Sarah Walker
Journal:  Trials       Date:  2020-05-18       Impact factor: 2.279

8.  Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.

Authors:  Laura Richert; Adélaïde Doussau; Jean-Daniel Lelièvre; Vincent Arnold; Véronique Rieux; Amel Bouakane; Yves Lévy; Geneviève Chêne; Rodolphe Thiébaut
Journal:  Trials       Date:  2014-02-26       Impact factor: 2.279

9.  Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study.

Authors:  Elisabeth Chéreau; Catherine Uzan; Emmanuelle Boutmy-Deslandes; Sarah Zohar; Corinne Bézu; Chafika Mazouni; Jean-Rémi Garbay; Emile Daraï; Roman Rouzier
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

10.  A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.

Authors:  Tomohiro Enokida; Takenori Ogawa; Akihiro Homma; Kenji Okami; Shujiro Minami; Ayako Nakanome; Yasushi Shimizu; Daisuke Maki; Yuri Ueda; Takao Fujisawa; Atsushi Motegi; Akira Ohkoshi; Jun Taguchi; Koji Ebisumoto; Shogo Nomura; Susumu Okano; Makoto Tahara
Journal:  Cancer Med       Date:  2020-01-13       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.